Behind almost every biotech IPO, every merger, and every buyout are a set of venture investors who stand to profit. In 2020, thanks to an extraordinary stock market and increased attention on the biopharma industry, those investors found themselves in a valuable spot.
Although relatively few pharmaceutical companies made big, flashy acquisition offers, investors were more than happy to welcome biotech companies onto the public markets. About 70 biotech companies made an initial public offering this year — including many that have yet to start a clinical trial — raising more than $14.5 billion.
About the Author Reprints
I am a STAT plus subscriber. I used my credentials to log in and I believe it is correct but I was not able to unlock the article.